Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination
Authors:
- Aurélien SokalASAurélien Sokal
- Paul BastardPBPaul Bastard
- Pascal ChappertPCPascal Chappert
- Giovanna Barba-SpaethGBGiovanna Barba-Spaeth
- Slim FouratiSFSlim Fourati
- Alexis VanderbergheAVAlexis Vanderberghe
- Pauline Lagouge-RousseyPLPauline Lagouge-Roussey
- Isabelle MeytsIMIsabelle Meyts
- Adrian GervaisAGAdrian Gervais
- Magali Bouvier-AliasMBMagali Bouvier-Alias
- Imane AzzaouiIAImane Azzaoui
- Ignacio FernándezIFIgnacio Fernández
Open Access
- 7 November 2022
- journal article
- research article
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 220 (1)
Abstract
Inborn and acquired deficits of type I interferon (IFN) immunity predispose to life-threatening COVID-19 pneumonia. We longitudinally profiled the B cell response to mRNA vaccination in SARS-CoV-2 naive patients with inherited TLR7, IRF7, or IFNAR1 deficiency, as well as young patients with autoantibodies neutralizing type I IFNs due to autoimmune polyendocrine syndrome type-1 (APS-1) and older individuals with age-associated autoantibodies to type I IFNs. The receptor-binding domain spike protein (RBD)–specific memory B cell response in all patients was quantitatively and qualitatively similar to healthy donors. Sustained germinal center responses led to accumulation of somatic hypermutations in immunoglobulin heavy chain genes. The amplitude and duration of, and viral neutralization by, RBD-specific IgG serological response were also largely unaffected by TLR7, IRF7, or IFNAR1 deficiencies up to 7 mo after vaccination in all patients. These results suggest that induction of type I IFN is not required for efficient generation of a humoral response against SARS-CoV-2 by mRNA vaccines.Keywords
This publication has 79 references indexed in Scilit:
- Toll-Like Receptor Signaling PathwaysFrontiers in Immunology, 2014
- mRNA-based therapeutics — developing a new class of drugsNature Reviews Drug Discovery, 2014
- Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNANucleic Acids Research, 2011
- Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activationNucleic Acids Research, 2010
- Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological StabilityMolecular Therapy, 2008
- Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloningJournal of Immunological Methods, 2008
- IFN Regulatory Factor Family Members Differentially Regulate the Expression of Type III IFN (IFN-λ) GenesThe Journal of Immunology, 2007
- Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNAImmunity, 2005
- mRNA Is an Endogenous Ligand for Toll-like Receptor 3Journal of Biological Chemistry, 2004
- STATs and Gene RegulationScience, 1997